clobetasol propionate ophthalmic nanoemulsion 0.05% (SVT-15473) / Laboratorios SALVAT - LARVOL DELTA

CLOSE-3: Clobetasol Propionate Ophthalmic Nanoemulsion, 0.05% in the Treatment of Inflammation After Cataract Surgery in Pediatric Population (clinicaltrials.gov) - P3 | N=60 | Recruiting | Sponsor: Salvat | Trial completion date: Aug 2024 ➔ Dec 2025 | Trial primary completion date: Aug 2024 ➔ Dec 2025

Surgery • Trial completion date • Trial primary completion date • Cataract • Inflammation • Ocular Inflammation • Ophthalmology • Pediatrics

Efficacy and safety of Clobetasol propionate ophthalmic nanoemulsion, 0.05% for the treatment of intraocular inflammation and pain associated with cataract surgery. (ARVO 2023) - "Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."

Clinical • Surgery • Cataract • Macular Edema • Ocular Inflammation • Ophthalmology

CLOSE-3: Clobetasol Propionate Ophthalmic Nanoemulsion, 0.05% in the Treatment of Inflammation After Cataract Surgery in Pediatric Population (clinicaltrials.gov) - P3 | N=60 | Recruiting | Sponsor: Salvat

New P3 trial • Cataract • Immunology • Inflammation • Ocular Inflammation • Ophthalmology • Pediatrics

Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-1) (clinicaltrials.gov) - P3; N=212; Completed; Sponsor: Salvat; Active, not recruiting ➔ Completed

Clinical • Trial completion • Cataract • Immunology • Inflammation • Ocular Inflammation • Ophthalmology • Pain

Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-1) (clinicaltrials.gov) - P3; N=210; Active, not recruiting; Sponsor: Salvat; Recruiting ➔ Active, not recruiting; Trial completion date: Nov 2020 ➔ May 2021; Trial primary completion date: Oct 2020 ➔ May 2021

Clinical • Enrollment closed • Trial completion date • Trial primary completion date • Cataract • Immunology • Inflammation • Ocular Inflammation • Ophthalmology • Pain

Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-2) (clinicaltrials.gov) - P3; N=215; Completed; Sponsor: Salvat; Recruiting ➔ Completed; Trial completion date: Nov 2020 ➔ Apr 2021; Trial primary completion date: Oct 2020 ➔ Apr 2021

Clinical • Trial completion • Trial completion date • Trial primary completion date • Cataract • Immunology • Inflammation • Ocular Inflammation • Ophthalmology • Pain

Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-2) (clinicaltrials.gov) - P3; N=210; Recruiting; Sponsor: Salvat; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Cataract • Immunology • Ocular Inflammation • Ophthalmology • Pain

Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-1) (clinicaltrials.gov) - P3; N=210; Recruiting; Sponsor: Salvat; Active, not recruiting ➔ Recruiting

Clinical • Enrollment open • Cataract • Immunology • Ocular Inflammation • Ophthalmology • Pain

Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-1) (clinicaltrials.gov) - P3; N=210; Active, not recruiting; Sponsor: Salvat; Not yet recruiting ➔ Active, not recruiting

Clinical • Enrollment closed • Cataract • Ocular Inflammation • Ophthalmology • Pain

Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-2) (clinicaltrials.gov) - P3; N=210; Not yet recruiting; Sponsor: Salvat

New P3 trial

Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-1) (clinicaltrials.gov) - P3; N=210; Not yet recruiting; Sponsor: Salvat

New P3 trial